Nanobiotix(NBTX) Newsfilter·2025-01-21 07:30Core Insights - Nanobiotix has initiated the CONVERGE study, a Phase 2 clinical trial for JNJ-1900 (NBTXR3) targeting Stage 3 unresectable non-small cell lung cancer, marking a significant step in its development pipeline [1][2] - The company emphasizes the potential of JNJ-1900 to meet the needs of patients undergoing radiotherapy, with a clear path to registration in head and neck cancer established through the NANORAY-312 study [2] - NBTXR3 is a novel oncology product utilizing hafnium oxide nanoparticles, designed to enhance tumor cell death when activated by radiotherapy, and has received a European CE mark for soft tissue sarcomas [3][4] Company Overview - Nanobiotix is a late-stage clinical biotechnology company focused on innovative therapeutic approaches to improve cancer treatment outcomes [6] - The company was founded in 2003 and is headquartered in Paris, France, with listings on Euronext Paris and Nasdaq [7] - Nanobiotix holds over 25 patents related to nanotechnology applications in oncology, bioavailability, and central nervous system disorders [8] Product Development - NBTXR3 is being evaluated in various solid tumor indications, both as a standalone treatment and in combination with anti-PD-1 immune checkpoint inhibitors [4] - The FDA granted Fast Track designation for NBTXR3 in the treatment of locally advanced head and neck squamous cell carcinoma [4] - Nanobiotix has established collaborations, including a partnership with The University of Texas MD Anderson Cancer Center, to expand the clinical development of NBTXR3 [5]